BRPI0811645A2 - Inibidores de transcriptase reversa de não-nucleosídeo - Google Patents
Inibidores de transcriptase reversa de não-nucleosídeoInfo
- Publication number
- BRPI0811645A2 BRPI0811645A2 BRPI0811645-8A2A BRPI0811645A BRPI0811645A2 BR PI0811645 A2 BRPI0811645 A2 BR PI0811645A2 BR PI0811645 A BRPI0811645 A BR PI0811645A BR PI0811645 A2 BRPI0811645 A2 BR PI0811645A2
- Authority
- BR
- Brazil
- Prior art keywords
- reverse transcriptase
- transcriptase inhibitors
- nucleoside reverse
- nucleoside
- inhibitors
- Prior art date
Links
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93225107P | 2007-05-30 | 2007-05-30 | |
| PCT/EP2008/056165 WO2008145562A1 (en) | 2007-05-30 | 2008-05-20 | Non-nucleoside reverse transcriptase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0811645A2 true BRPI0811645A2 (pt) | 2014-11-11 |
Family
ID=39712538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0811645-8A2A BRPI0811645A2 (pt) | 2007-05-30 | 2008-05-20 | Inibidores de transcriptase reversa de não-nucleosídeo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8026362B2 (pt) |
| EP (1) | EP2155692B1 (pt) |
| JP (1) | JP5167350B2 (pt) |
| KR (1) | KR101542629B1 (pt) |
| CN (1) | CN101679294B (pt) |
| AR (1) | AR066743A1 (pt) |
| AU (1) | AU2008257771B2 (pt) |
| BR (1) | BRPI0811645A2 (pt) |
| CA (1) | CA2687747C (pt) |
| CL (1) | CL2008001537A1 (pt) |
| EA (1) | EA016386B1 (pt) |
| ES (1) | ES2542153T3 (pt) |
| IL (1) | IL202143A (pt) |
| MX (1) | MX2009012704A (pt) |
| PE (1) | PE20090296A1 (pt) |
| TW (1) | TWI425946B (pt) |
| WO (1) | WO2008145562A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001631A1 (es) * | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
| DE102008030091B4 (de) * | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
| EP3774804A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| EP3797100A4 (en) | 2018-05-23 | 2022-06-15 | Mor Research Applications Ltd. | TOLL-LIKE RECEPTORS 4 (TLR4) INHIBITORS AND THEIR USE |
| MX2021007382A (es) | 2018-12-18 | 2021-07-15 | Merck Sharp & Dohme Llc | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih. |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110470A (en) * | 1965-10-07 | 1978-08-29 | Horst Kummer | Pharmaceutical composition comprising d,l-α-methyl-thyroxine ethyl ester and the salts thereof and the control of cholesterol and triglyceride blood level therewith |
| US4949314A (en) | 1966-08-16 | 1990-08-14 | The United States Of America As Represented By The Secretary Of The Navy | Method and means for increasing echo-ranging-search rate |
| GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| GB8327880D0 (en) | 1983-10-18 | 1983-11-16 | Ajinomoto Kk | Saccharomyces cerevisiae |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| IL76360A0 (en) | 1984-09-26 | 1986-01-31 | Takeda Chemical Industries Ltd | Mutual separation of proteins |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| AU622926B2 (en) | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
| US5925643A (en) | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
| US5489697A (en) | 1994-08-03 | 1996-02-06 | Medichem Research, Inc. | Method for the preparation of (+)-calanolide A and intermediates thereof |
| IL117574A0 (en) | 1995-04-03 | 1996-07-23 | Bristol Myers Squibb Co | Processes for the preparation of cyclobutanone derivatives |
| US7166730B2 (en) | 2000-01-27 | 2007-01-23 | Fine Tech Laboratories, Ltd | Process for the preparation of prostaglandin derivatives |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| JP4107658B2 (ja) | 2003-07-23 | 2008-06-25 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 分類因子検出装置、分類因子検出方法、プログラム、及び記録媒体 |
| JP4848355B2 (ja) | 2004-02-27 | 2011-12-28 | アンスティテュ・キュリ | 臨床診療における新規増殖マーカーおよび癌の予後または診断のためのそれらの用途 |
| EP1730120A1 (en) * | 2004-03-23 | 2006-12-13 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| EP1737827A1 (en) | 2004-04-15 | 2007-01-03 | F.Hoffmann-La Roche Ag | Process for preparing pyridazinone compounds |
| US7625949B2 (en) | 2004-04-23 | 2009-12-01 | Roche Palo Alto Llc | Methods for treating retroviral infections |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| CA2471006A1 (en) * | 2004-06-23 | 2005-12-23 | Bayer Inc. | Silica reinforced elastomer compounds prepared with dry liquid modifiers |
| ES2391461T3 (es) | 2004-07-27 | 2012-11-27 | F. Hoffmann-La Roche Ag | Compuestos de benciltriazolona utilizados como inhibidores no nucleósidos de transcriptasa inversa |
| ME01512B (me) | 2004-08-25 | 2014-04-20 | Ardea Biosciences Inc | S-triazolil alfa-merkaptoacetanilida kao inhibitori HIV reversne transkriptaze |
| AU2005305609B2 (en) | 2004-09-17 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Phosphoindoles as HIV inhibitors |
| WO2006034583A1 (en) | 2004-09-30 | 2006-04-06 | Boehringer Ingelheim International Gmbh & Co Kg | Alkynyl based dervatives of benzophenone as non-nucleoside reverse transcriptase inhibitors |
| JP4423166B2 (ja) | 2004-10-29 | 2010-03-03 | 富士通株式会社 | 電子部品の超音波実装方法および超音波実装装置 |
| JP2008525419A (ja) | 2004-12-22 | 2008-07-17 | ファイザー・リミテッド | Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤 |
| EP1863777A1 (en) * | 2005-03-24 | 2007-12-12 | F.Hoffmann-La Roche Ag | 1,2,4 -triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors |
| US20060225874A1 (en) | 2005-04-11 | 2006-10-12 | Shives Gary D | Sandwiched thermal article |
| AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| BRPI0617205A2 (pt) * | 2005-09-30 | 2011-07-19 | Hoffmann La Roche | inibidores de nnrt |
| ES2320042T3 (es) | 2005-10-19 | 2009-05-18 | F. Hoffmann-La Roche Ag | Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida. |
| EP1940781A1 (en) | 2005-10-19 | 2008-07-09 | F.Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
| WO2009000663A1 (en) * | 2007-06-22 | 2008-12-31 | F. Hoffmann-La Roche Ag | Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors |
-
2008
- 2008-05-20 BR BRPI0811645-8A2A patent/BRPI0811645A2/pt not_active IP Right Cessation
- 2008-05-20 EA EA200901599A patent/EA016386B1/ru not_active IP Right Cessation
- 2008-05-20 WO PCT/EP2008/056165 patent/WO2008145562A1/en not_active Ceased
- 2008-05-20 CN CN2008800179226A patent/CN101679294B/zh not_active Expired - Fee Related
- 2008-05-20 ES ES08759780.3T patent/ES2542153T3/es active Active
- 2008-05-20 MX MX2009012704A patent/MX2009012704A/es active IP Right Grant
- 2008-05-20 AU AU2008257771A patent/AU2008257771B2/en not_active Ceased
- 2008-05-20 CA CA2687747A patent/CA2687747C/en not_active Expired - Fee Related
- 2008-05-20 KR KR1020097027313A patent/KR101542629B1/ko not_active Expired - Fee Related
- 2008-05-20 EP EP08759780.3A patent/EP2155692B1/en not_active Not-in-force
- 2008-05-20 JP JP2010509787A patent/JP5167350B2/ja not_active Expired - Fee Related
- 2008-05-27 PE PE2008000903A patent/PE20090296A1/es not_active Application Discontinuation
- 2008-05-28 AR ARP080102236A patent/AR066743A1/es unknown
- 2008-05-28 CL CL2008001537A patent/CL2008001537A1/es unknown
- 2008-05-29 TW TW097119955A patent/TWI425946B/zh not_active IP Right Cessation
- 2008-05-30 US US12/156,228 patent/US8026362B2/en not_active Expired - Fee Related
-
2009
- 2009-11-15 IL IL202143A patent/IL202143A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US8026362B2 (en) | 2011-09-27 |
| CN101679294A (zh) | 2010-03-24 |
| ES2542153T3 (es) | 2015-07-31 |
| JP2010528083A (ja) | 2010-08-19 |
| KR101542629B1 (ko) | 2015-08-06 |
| WO2008145562A1 (en) | 2008-12-04 |
| CN101679294B (zh) | 2012-08-08 |
| CA2687747A1 (en) | 2008-12-04 |
| CL2008001537A1 (es) | 2008-12-05 |
| PE20090296A1 (es) | 2009-03-27 |
| KR20100028584A (ko) | 2010-03-12 |
| CA2687747C (en) | 2015-11-17 |
| TWI425946B (zh) | 2014-02-11 |
| EA016386B1 (ru) | 2012-04-30 |
| JP5167350B2 (ja) | 2013-03-21 |
| AU2008257771A1 (en) | 2008-12-04 |
| TW200911260A (en) | 2009-03-16 |
| AU2008257771B2 (en) | 2015-02-19 |
| EA200901599A1 (ru) | 2010-06-30 |
| AR066743A1 (es) | 2009-09-09 |
| US20090076045A1 (en) | 2009-03-19 |
| EP2155692A1 (en) | 2010-02-24 |
| IL202143A0 (en) | 2010-06-16 |
| IL202143A (en) | 2014-06-30 |
| MX2009012704A (es) | 2009-12-08 |
| EP2155692B1 (en) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813269A2 (pt) | Inibidores de hiv transcriptase reversa | |
| BRPI0715193A2 (pt) | inibidores nço-nucleosÍdicos da transcriptase reversa | |
| IL199103A0 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| EP2076492A4 (en) | NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS | |
| IL205386A0 (en) | Non - nucleoside reverse transcriptase inhibitors | |
| LTPA2019506I1 (lt) | Nenukleozidinės reversinės transkriptazės inhibitoriai | |
| EP2217069A4 (en) | INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE | |
| CY2017016I2 (el) | Αναστολεις πρωτεασωματος | |
| EP2220091A4 (en) | REVERSE transcriptase inhibitors | |
| IL200748A0 (en) | Non-nucleoside reverse transcriptse inhibitors | |
| BRPI0818294A2 (pt) | refrigerador | |
| DK2139892T3 (da) | Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer | |
| NO20161397A1 (no) | Ikke-nukleosidbaserte revers-transkriptase-inhibitorer | |
| DK2383271T3 (da) | Aminoquinoloner som GSK-3-inhibitorer | |
| BRPI0819260A2 (pt) | refrigerador | |
| BRPI0820345A2 (pt) | refrigerador | |
| EP2226593A4 (en) | FREEZER UNIT | |
| EP2204584A4 (en) | Screw fluid machine | |
| BRPI0810496A2 (pt) | inibidores de transcriptase reversa de não-nucleosídeo | |
| IL202143A0 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| BRPI0714509A2 (pt) | Inibidores de transcriptase reversa de não-nucleosídeo. | |
| ATE518854T1 (de) | Arylcarbonsäurecyclohexylamidderivate | |
| EP1899340A4 (en) | NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS | |
| FI20075320A0 (fi) | Uusia käyttökelpoisia inhibiittoreita | |
| HK1131985A (en) | Non-nucleoside reverse transcriptase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |